Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03775499
Other study ID # 17.11.NRC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 9, 2018
Est. completion date December 15, 2020

Study information

Verified date December 2020
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.


Description:

This trial is a multicenter, double blind, randomized, placebo controlled, 2 by 2 cross-over design (i.e. 2-sequences, 2-periods, 2-treatments) for each specific population (i.e. self-reported Non Coeliac Gluten Sensitivity and Coeliac Disease subjects). 1 capsule of BL NCC 2705 or placebo will be given twice a day in the morning and in the evening with a meal over 2 periods of 4 days. On day four a single dose of gluten (3g) will be administered and duodenal fluid will be collected in the following hours through a naso-intestinal catheter. The viability of BL NCC 2705, the production of serpin and its effects on gluten digestion and intestinal enzymatic activity will be determined. No chronic administration of gluten as a challenge is foreseen in the study. After a wash out period of minimum 2 weeks, period will be repeated.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date December 15, 2020
Est. primary completion date October 4, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Willing and able to sign written informed consent prior to trial entry 2. Male or female adults >18 years of age 3. For NCGS: self-reported gluten sensitivity with negative CD serology, on gluten free diet for at least 6 weeks with self-reported significant symptomatic improvement 4. For CD: confirmed serologic and histologic diagnosis of CD and on GFD for at least 12 months with self-reported significant symptomatic improvement 5. Body Mass Index (BMI) within the range >18 - <30 kg/m2 6. Willing and able to comply with study procedures and restrictions 7. In good health as determined by a medical history and medical examination Exclusion Criteria: 1. Documented IgE-mediated food allergy 2. Subjects following an overly imbalanced or restrictive diet as per nutritional advice 3. Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be detrimental for the participants safety or potentially interfering with the study procedures and/or study outcomes 4. Concurrent organic GI pathology other than benign polyps, diverticulosis, hemorrhoids, lipomas and melanosis coli 5. Previous abdominal surgery with the exception of hernia repair, appendectomy, caesarian section, tubal ligation, hysterectomy, hemorrhoidectomy 6. Patients who received antibiotics in the previous 2 weeks 7. women of childbearing potential not willing to use an effective contraception method

Study Design


Intervention

Dietary Supplement:
Intervention 1 : BL NCC 2705 + Maltodextrin
2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
Other:
Intervention 1 : Maltodextrin
2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
Dietary Supplement:
Intervention 2 : BL NCC 2705 + Maltodextrin
2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
Other:
Intervention 2 : Maltodextrin
2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day

Locations

Country Name City State
Netherlands Viecuri Hospital Venlo

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence, type and severity of adverse event incidence, type and severity of adverse event from Baseline to end of study (up to maximum 43 days)
Primary Gastro-intestinal tolerability: visual analog scale Sum of visual analog scale for gastro-intestinal symptoms assessment (nausea, vomiting, diarrhea, audible bowel sound, flatulence and abdominal cramping symptoms are assessed). Each scale is from 0 (no symptom) to 100mm (maximum symptom). The maximum sum value is 600. from Baseline to end of study (up to maximum 43 days)
Secondary Concentration of bacterial Serpin RNA and/or proteins (ng/mL) in duodenal aspirates Measurements via RT-PRC and immuno-assay 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Secondary Concentration of Probiotic BL NCC 2705 (ng/mL) in duodenal aspirates Measurements via PCR 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Secondary Concentration of gluten derived pepides in duodenal aspirates Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in duodenal apsirates 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Secondary Concentration of gluten derived pepides in urine Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in urine 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Secondary Level of elastase (Units/ mL) activity in duodenal aspirates Measurements of proteolytic activity based assay 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
See also
  Status Clinical Trial Phase
Completed NCT04349904 - Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Completed NCT04593251 - Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis Phase 1
Completed NCT05810441 - Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
Recruiting NCT05555446 - Bovine Colostrum to Prevent Absorption of Gluten Early Phase 1
Completed NCT02754609 - Hookworm Therapy for Coeliac Disease Phase 1
Terminated NCT01902368 - Celiac Disease Screening N/A
Completed NCT02312349 - Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
Completed NCT02472704 - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo N/A
Completed NCT01172665 - Celiac Disease Database
Completed NCT01100099 - HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Phase 2/Phase 3
Completed NCT00639444 - Risk of Celiac Disease and Age at Gluten Introduction N/A
Active, not recruiting NCT05425446 - Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients Phase 1
Enrolling by invitation NCT02202681 - Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule N/A
Completed NCT00362856 - Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects Phase 2
Terminated NCT03866538 - Budesonide in Patients With Immune Mediated Enteropathies Phase 4
Recruiting NCT05135923 - Glutenfree, Gut Microbiota and Metabolic Regulation N/A
Completed NCT05052164 - Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women N/A
Completed NCT03707730 - A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives